Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ETC-1907206 + Irinotecan |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ETC-1907206 | ETC-206|AUM001|AUM-001|ETC206|ETC 206 | ETC-1907206 is an inhibitor of MAPK interacting serine/threonine kinases (MKNK1, MKNK2), which inhibits the phosphorylation of eIF4E to prevent inflammation and cell proliferation (PMID: 31343094, PMID: 29683667). | ||
Irinotecan | Camptosar | CPT-11 | TOPO1 inhibitor 11 | Camptosar (irinotecan) inhibits Topoisomerase-I activity, resulting in inhibition of DNA replication, and potentially leading to cell death and is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic or recurrent colorectal carcinoma (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05462236 | Phase II | ETC-1907206 ETC-1907206 + Irinotecan ETC-1907206 + Pembrolizumab | MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer | Recruiting | AUS | 0 |